Cominar REIT (CUF.UN) Analysts See $0.35 EPS; Macquarie Group LTD Has Trimmed Its Abbott Laboratories (ABT) Position

August 3, 2017 - By Darrin Black

Analysts expect Cominar REIT (TSE:CUF.UN) to report $0.35 EPS on August, 4 before the open.They anticipate $0.07 EPS change or 16.67% from last quarter’s $0.42 EPS. T_CUF’s profit would be $64.44M giving it 9.35 P/E if the $0.35 EPS is correct. After having $0.33 EPS previously, Cominar REIT’s analysts see 6.06% EPS growth. The stock decreased 0.30% or $0.04 on August 2, reaching $13.09. About 291,277 shares traded. Cominar REIT (TSE:CUF.UN) has 0.00% since August 3, 2016 and is . It has underperformed by 16.70% the S&P500.

Macquarie Group Ltd decreased Abbott Laboratories (ABT) stake by 0.11% reported in 2016Q4 SEC filing. Macquarie Group Ltd sold 22,500 shares as Abbott Laboratories (ABT)’s stock declined 3.42%. The Macquarie Group Ltd holds 19.69 million shares with $756.45M value, down from 19.72M last quarter. Abbott Laboratories now has $85.43B valuation. The stock increased 0.16% or $0.08 during the last trading session, reaching $49.23. About shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since August 3, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Cominar REIT is a Canada-based real estate investment trust . The company has market cap of $2.41 billion. The Firm is a commercial property owner and manager in the province of Quebec. It has a 9.76 P/E ratio. The Company’s divisions include Office, Retail, and Industrial and mixed-use.

Among 5 analysts covering Cominar Real Estate Investment Trust (TSE:CUF.UN), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Cominar Real Estate Investment Trust has $20.50 highest and $14 lowest target. $15.31’s average target is 16.96% above currents $13.09 stock price. Cominar Real Estate Investment Trust had 19 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by National Bank Canada on Friday, September 23 with “Outperform”. The firm earned “Sector Perform” rating on Friday, March 10 by Scotia Capital. The rating was maintained by Scotia Capital on Friday, November 4 with “Sector Perform”. The stock has “Buy” rating by TD Securities on Friday, August 7. As per Friday, March 10, the company rating was maintained by TD Securities.

Since February 13, 2017, it had 0 insider buys, and 19 insider sales for $7.50 million activity. On Tuesday, February 28 YOOR BRIAN B sold $78,434 worth of Abbott Laboratories (NYSE:ABT) or 1,728 shares. Watkin Jared sold $24,965 worth of stock. 13,155 shares were sold by Contreras Jaime, worth $592,157 on Tuesday, February 28. $6,567 worth of Abbott Laboratories (NYSE:ABT) was sold by MANNING JOSEPH J on Friday, February 17. The insider Salvadori Daniel Gesua Sive sold 2,066 shares worth $93,776. 1,912 Abbott Laboratories (NYSE:ABT) shares with value of $86,068 were sold by Mason Heather L. Another trade for 319 shares valued at $14,349 was made by NATH DEEPAK S. on Friday, February 17.

Among 22 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 8 Hold. Therefore 64% are positive. Abbott Laboratories has $90 highest and $4 lowest target. $51.78’s average target is 5.18% above currents $49.23 stock price. Abbott Laboratories had 65 analyst reports since July 24, 2015 according to SRatingsIntel. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Monday, June 26 with “Buy” rating. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by BTIG Research on Wednesday, June 21. Gabelli maintained the stock with “Buy” rating in Friday, July 21 report. The stock of Abbott Laboratories (NYSE:ABT) has “Outperform” rating given on Friday, January 29 by RBC Capital Markets. Jefferies maintained the shares of ABT in report on Tuesday, June 14 with “Buy” rating. The firm has “Buy” rating given on Wednesday, April 19 by Stifel Nicolaus. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, July 23. The firm earned “Buy” rating on Friday, July 21 by Deutsche Bank. As per Friday, February 5, the company rating was upgraded by Argus Research. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Edward Jones on Tuesday, June 21.